Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Drug Discovery
- Disease
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 300741
Licensor grants an exclusive license, including the right to sublicense, under Licensors rights in the Licensor Technology, to use, copy, distribute and create derivative works of Licensor Technology to make, use, offer for sale, sell and import Licensed Products worldwide.
This agreement includes non-exclusive grants back from Licensee.
D-DM means any compound having the structure of dextromethorphan, or a salt, solvate, or hydrate thereof, wherein for a given sample of the compound, the abundance of deuterium at one or more of the hydrogens of dextromethorphan is greater than the natural abundance of deuterium. The term D-DM also includes dextromethorphan metabolites.
D-DM Analog means any compound wherein R I is hydrocarbyl of one to four carbons or -O-R2 wherein R2 is -CH2F, CHF2, CF3 or hydrocarbyl of two to four Carbons or a salt, solvate or hydrate thereof wherein for a given sample of the compound the abundance of deuterium at one or more of the hydrogens of the structure, including any of the hydrogens of the aforementioned hydrocarbyl of one to four carbons, -CH2F, -CHF2, hydrocarbyl of two to four carbons, or any of the hydrogens of the depicted N-methyl is greater than the natural abundance of deuterium. The term D-DM analog also includes metabolites of any compound having the structure described.
D-DM and Quinidine Product means a Licensed Product that contains or is administered with quinidine in accordance with the approved label for such Licensed Product.
D-DM Only Product means a Licensed Product that is not a D-DM and Quinidine Product.
Deuterated Products means a compound, wherein for a given sample of the compound, the abundance of deuterium at one or more of the hydrogens of the compound is greater than the natural abundance of deuterium.
IPSCIO Record ID: 280835
United States Patent Number 5,166,207, 'Method for Enhancing the Systemic Delivery of Dextromethorphan for the Treatment of Neurological Disorders'
United States Patent Number 5,166,207, 'Method for Enhancing the Systemic Delivery of Dextromethorphan for the Treatment of Neurological Disorders'
United States Patent Number 5,350,756, 'Use of a Cytochrome Oxidase Inhibitor to Increase the Cough-Suppressing Activity of Dextromethorphan'
United States Patent Number 5,366,980, 'Use of extromethorphan and an Oxidase Inhibitor to Treat Dermatitis'
United States Patent Number 5,863,927, 'Dextromethorphan and an Oxidase Inhibitor for Treating Intractable Conditions'
PCT Application PCT/US94/10771, 'Compositions Useful for the
Preparation of Medicines for Treating a Variety of Intractable Disorders'
United States Patent Application Number 09/471,060, filed December 22, 1999, entitled 'Dextromethorphan and Oxidase Inhibitor for Weaning Patients from Narcotics and Anti-Depressants'
(i) EMOTIONAL LABILITY INDICATION.
(ii) CHRONIC PAIN INDICATION.
(iii) CHRONIC COUGH INDICATION.
(iv) DERMATITIS INDICATION.
(v) PRODUCTS FOR WEANING PATIENTS FROM NARCOTICS AND ANTI-DEPRESSANTS.
Emotional lability refers to rapid, often exaggerated changes in mood, where strong emotions or feelings (uncontrollable laughing or crying, or heightened irritability or temper) occur.
Dermatitis, also known as eczema, is a group of diseases that result in inflammation of the skin.
IPSCIO Record ID: 372521
Licensee has the right to develop and commercialize the PET Ligand as set forth.
Licensor patents and technology relate to Imidazole Derivatives. The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).
The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.
The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.
The term EVT 101 shall mean xO-4394127.
The term EVT 103 shall mean xO-0717626.
The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimer’s disease, neuropathic pain and Parkinson’s Disease.
